Compare LYTS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | ANNX |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 730.4M |
| IPO Year | 1994 | 2020 |
| Metric | LYTS | ANNX |
|---|---|---|
| Price | $19.07 | $5.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $27.50 | $16.50 |
| AVG Volume (30 Days) | 217.5K | ★ 2.4M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $573,377,000.00 | N/A |
| Revenue This Year | $11.92 | N/A |
| Revenue Next Year | $17.72 | $22,605.10 |
| P/E Ratio | $44.51 | ★ N/A |
| Revenue Growth | ★ 22.09 | N/A |
| 52 Week Low | $13.77 | $1.40 |
| 52 Week High | $24.75 | $7.18 |
| Indicator | LYTS | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 55.27 |
| Support Level | $18.19 | $4.79 |
| Resistance Level | $19.41 | $6.50 |
| Average True Range (ATR) | 0.76 | 0.44 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 39.42 | 66.67 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.